Clinical Trial Update: BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating BMS-813160 in combination with nivolumab, gemcitabine, and nab-paclitaxel in borderline resectable and locally advanced panc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• BMS-813160
• Gemcitabine (Gemcitabine)
• OPDIVO (nivolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-30